Trials / Completed
CompletedNCT05616598
Effect of New Oral Treatment for Hepatitis C Virus on Seminal Parameters
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 200 (actual)
- Sponsor
- Benha University · Academic / Other
- Sex
- Male
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
Hepatitis C virus is commona viral infection. Direct-acting antiviral (DAA) oral drugs has been used in treatment of HCVs. the effect of these drugs on male infertility is still under investigation.
Detailed description
Semen analysis will be done to male patients with HCV before and after treatment with DAA. The included men will take therapy for 3 months and HCV RNA titter will be evaluated. changes of seminal parameters will be recorded and analyzed.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sofosbuvir +daclatasvir+ simeprevir+Ribavirin | Oral daily dose of Sofosbuvir +daclatasvir + simeprevir+ Ribavirin for 3 months |
Timeline
- Start date
- 2022-03-01
- Primary completion
- 2022-11-25
- Completion
- 2022-12-31
- First posted
- 2022-11-15
- Last updated
- 2023-02-08
Locations
2 sites across 1 country: Egypt
Source: ClinicalTrials.gov record NCT05616598. Inclusion in this directory is not an endorsement.